KROS

KEROS THERAPEUTICS INC

Healthcare | Micro Cap

-$0.97

EPS Forecast

$9.3

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Keros Therapeutics (KROS) Wirings in the TGF-β Garden: Phase 2 DMD dosing, nonclinical ker-206 nod, and a cash runway past 2028

From a financial disclosures perspective, this is a biotech update with a dash of license revenue and a cautionary note about dependency on milestones. For traders, the key SEO-ready anchors are KROS, EPS, EPS consensus, earnings surprise, and revenue forecast as the narrative twists through quarterly results and pipeline milestones.

Overview: a quarterly update anchored by a cash runway and a portfolio update

Keros Therapeutics, Inc. (Nasdaq: KROS) delivered its third-quarter 2026 update. The headline numbers show a shift from net loss to net income on a quarterly basis, driven in part by revenue recognized under a Takeda license agreement. The company also flagged meaningful clinical and nonclinical program updates, including the first patient dosed in a Phase 2 trial of rinvatercept for Duchenne muscular dystrophy (DMD) and the nomination of KER-206 for further investigation in nonclinical work on bone remodeling.

In the parlance of the street, this is a story about cash, not just cures—cash runway is projected into the second half of 2028, a helpful horizon for a company balancing stage-gate progress with the plate of ongoing R&D. And for the street’s tickers, the presence or absence of an EPS figure or a revenue forecast can be a talking point—even if this press release doesn’t publish an EPS number or formal revenue guidance.

Financial snapshot: a quarter buoyed by license revenue, with continued investment in the pipeline

  • Net income for Q3 2026: $14.2 million, versus a net loss of $7.3 million in Q3 2025. The swing is notable and largely attributed to revenue recognized under the Takeda collaboration.
  • R&D expenses were $20.5 million for the quarter, up from $19.5 million year-over-year, reflecting continued nonclinical and clinical work to advance the pipeline.
  • General and administrative expenses totaled $6.7 million, down meaningfully from $10.1 million a year ago, driven by lower compensation costs and professional fees.
  • Cash and cash equivalents stood at $259.5 million as of September 30, 2026, down from $287.4 million at December 31, 2025. The company expects this liquidity to fund operating expenses and capital expenditures into the second half of 2028.
  • There is no explicit EPS figure disclosed in the release, and no formal revenue forecast is provided. In investor terms, that means the EPS consensus and earnings surprise figures remain undetermined from this filing, at least in a press-release sense.

Recent program updates: Rinvatertcept in DMD and the KER-206 pathway

  • Rinvatercept for DMD: In September 2026, the first patient was dosed in a Phase 2 trial. Initial data are targeted for the first half of 2027. The milestone is not a financial forecast, but it does set a near-term data cadence that could influence sentiment around the stock and the sector’s appetite for TGF-β-targeted strategies.
  • KER-206: The company nominated KER-206 from its nonclinical portfolio for further investigation. KER-206 is described as a nonclinical asset designed to bind select TGF-β ligands involved in bone remodeling (activin A/B, GDF8, GDF11), a potential lever to increase bone mass and improve skeletal integrity in disorders with pathological bone loss.
  • Nonclinical poster: A poster (RKER-206) was presented at a major bone and mineral research meeting, highlighting preclinical work around this approach. The emphasis remains on translating nonclinical signals into clinical hypotheses, with no explicit revenue forecast attached to these pipeline steps.

From the CEO chair: what the numbers and milestones portend

Jasbir S. Seehra, Ph.D., CEO, framed the quarter as a continuation of disciplined execution across clinical and nonclinical programs, underscoring a strategic push to leverage TGF-β biology for meaningful patient impact. The emphasis on “discipline” rings a familiar bell in biotech journalism: progress is measured in patient milestones and data releases, not just quarterly headlines.

Beyond the press release boilerplate, the story here is twofold: progress on the rinvatercept DMD program could matter if early Phase 2 data reveal a robust signal, while KER-206’s nonclinical advancement keeps the door open for broader TGF-β–modulating strategies, potentially shaping collaborators and licensing discussions in a crowded space of folks trying to fix bone and muscle problems.

outlook: a cash runway and a pipeline that outlives the headlines

The company’s cash position—roughly $259.5 million as of September 30, 2026—offers a runway into late 2028, assuming operating assumptions hold. That horizon is valuable in biotech terms: it matters for milestones, partner negotiations, and the ability to de-risk the pipeline without urgent capital raises. The absence of a stated revenue forecast underscores the sector reality that much of the value remains in science milestones, not near-term revenue streams.

Analysts and investors will watch for any shift in the revenue recognition profile tied to Takeda and for data reads from rinvatercept and KER-206. If the quarter’s earnings surprise (positive or negative) hinges on non-GAAP adjustments or one-off licensing revenue, that could prompt a sharper near-term re-rating than a straightforward read on GAAP earnings. In other words: the stock moves with data cadence, not just quarterly totals.

Sector implications: what this signals for peers in the TGF-β and bone remodeling space

The Q3 discipline at KROS contributes to a broader narrative in the TGF-β ecosystem: partnerships and license economics can meaningfully affect quarterly performance, even when core pipeline risk remains. For peers, the message is that a well-timed data read from Rinvatertcept and continued nonclinical advances could influence partnerships and potential licensing revenue (the lifeblood of many late-stage biotech plays). The emphasis on a robust cash runway also serves as a reminder that capital sustainability matters as much as clinical milestones in sustaining long-range development plans.

Bottom line: a quarterly update that trades a little science for a lot of runway—and that’s a formula investors can ink in ink

For the KROS narrative, the headline is not a single number but a constellation: a Q3 net income bump tied to license revenue, ongoing R&D investment, a notable DMD Phase 2 milestone, and a cash cushion stretching to late 2028. The absence of a disclosed EPS figure or revenue forecast means the market must rely on pipeline momentum and the durability of Takeda’s collaboration for near-term valuation. If you’re indexing this for an EPS consensus read, you’ll be waiting for the data readouts and per-share metrics to arrive in subsequent quarters. In the meantime, the company’s capital position and pipeline milestones give the stock a runway of its own—one that could outpace the quarter’s headline numbers if data lands as hoped.

Note: This summary reflects the information contained in Keros Therapeutics’ Exhibit 99.1 press release for the quarter ended September 30, 2026. All numbers are in U.S. dollars unless noted otherwise. This is not investment advice.